Influence of Angiotensin Receptor Blocker (Candesartan) and Angiotensin-Converting-Enzyme Inhibitor (Enalapril) Combined with Glimepiride on Glycated Hemoglobin in Non-Insulin Dependent Diabetic Rats (NIDDM)

Main Article Content

Abdulwahab Al-Badri
Eyad Mallah
Zainab Zakarya
Ramadan Al-Shdefat
Feras Darwish El-Hajji
Mo’ath Ifraitekh
Abeer Kharshid
Wael Abu Dayyih

Abstract

Background: Antihypertensive agents like Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Converting Enzyme Blockers (ARBs) are commonly indicated for patients with both hypertension and diabetes. However, the effect of these agents on blood sugar level or glycated hemoglobin (HbA1c) is still controversial. This study aims at investigating the short, and long term effects of ACEIs and ARBs on blood sugar level and HbA1c of a group of streptozocin (STZ)-induced NIDDM rats when given in combination with Glimepiride (antidiabetic drug from Sulfonylureas group).

Methods: Diabetes mellitus (DM) was induced in 100 Wistar albino adult male and female laboratory rats above 8 weeks old, and weigh between 250-300 gm by the administration of Streptozocin 75% α-anomer. Two weeks later, the 100 rats were then randomized into four groups (25 rats each). Group one was the untreated control group (received placebo only), while other groups (II, III, and IV) were treated by Glimepiride only, Glimepiride plus ARB (Candesartan), and Glimepiride plus ACEI (Enalapril) respectively. HbA1C levels were measured at baseline (pre-test/directly after randomization) to ensure that there was no significant difference between study groups at the baseline, post-test (after two weeks), and delayed-post-test (12 weeks after randomization/ 10 weeks after post-test) to measure short and long-term changes in the study groups.

Results: There was no significant difference (p-values >0.05) between the four groups (groups I, II, III, and IV) in the HbA1C mean level at the beginning of this study (two-weeks after randomization and injection of STZ) (mean = 7.62 ±SD = 0.41, 7.72 ±SD = 0.48, 7.66 ±SD = 0.47, and 7.52 ±SD = 0.51respectively). However, two weeks later, treated groups (groups II, III, and IV) showed moderate reduction of HbA1C mean level compared to the untreated (placebo) group I, that was significant in groups III, and IV, and insignificant in group II (mean =7.43±SD 0.54, 6.97±SD 0.33, 6.72±SD 0.26, and 7.71 ±SD 0.44 respectively). Furthermore, treated groups (groups II, III, and IV) showed significant dramatic reduction of HbA1C mean level when compared to the untreated group (group I) (mean = 6.22 ±SD 0.51, 5.24 ±SD 0.62, 5.22 ±SD 0.13, and 7.62 ±SD 0.42 respectively).Overall, treated groups showed significantly lower HbA1C level than placebo groups. Moreover, Glimepiride + Enalapril combination showed a stronger hypoglycemic effect than the Glimepiride + Candesartan combination at post, and post-delayed tests, however, these differences were not significant.

Conclusion: The addition of either ACEIs like Enalapril, or ARBs like Candesartan to Sulfonylureas like Glimepiride to in NIDDM patients will synergize its anti-diabetic effect in NIDDM subjects, and might increase the possibility of hypoglycemia. Caution and/or dose adjustment should be considered upon using these agents together in patients with hypertension along with diabetes.

Keywords:
Candesartan, Enalapril, dependent diabetic, HbA1c, glimepiride

Article Details

How to Cite
Al-Badri, A., Mallah, E., Zakarya, Z., Al-Shdefat, R., El-Hajji, F. D., Ifraitekh, M., Kharshid, A., & Dayyih, W. A. (2020). Influence of Angiotensin Receptor Blocker (Candesartan) and Angiotensin-Converting-Enzyme Inhibitor (Enalapril) Combined with Glimepiride on Glycated Hemoglobin in Non-Insulin Dependent Diabetic Rats (NIDDM). Journal of Pharmaceutical Research International, 32(9), 40-51. https://doi.org/10.9734/jpri/2020/v32i930481
Section
Original Research Article

References

Klein E. a 411-3720 09-11. 2005;8–9.

Forouzanfar MH, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational and metabolic risks or clusters of risks in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(10010):2287–2323.

Okpechi. Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction. Integr. Blood Press. Control. 2010;45.

Ripley TL, Chonlahan JS, Germany RE. Candesartan in heart failure. Clin. Interv. Aging. 2006;1(4):357–366.

Husain A, Azim Md Sabir MS, Mitra M, Bhasin PS. A review on candesartan: Pharmacological and pharmaceutical profile. J. Appl. Pharm. Sci. 2011;1(10):12–17.

Wael Abu Dayyih, et al. A study of the possible effect of pomegranate juice on the pharmacokinatics of candesartan in rat plasma by using a bioanalytical method- liquid chromatography/mass spectrometry (HPLC/MS/MS). IJPT. 2016;8(1):10200-10216.

Full Prescribing Information Warning: Fetal Toxicity [See Warnings and Precautions (5.1)] Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. [See Warnings and Precautions (5.1)] Indications and usage hypertension achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC). treatment to a lower blood pressure goal. patients and many antihypertensive drugs have additional approved indications and effects selection of therapy thiazide-type diuretics. The blood pressure lowering effects of EPANED and thiazides are; 1985.

Wael Abu Dayyih, et al. A liquid chromatography-Tandem mass spectrometry method for evaluation of two brands of Enalapril 20 mg tablets in healthy human volunteers. Journal of Analytical Methods in Chemistry. 2017;8. Article ID: 8489471.

Ukwueze SE, Anthony DN. An ultraviolet-visible (UV-vis) spectrophotometric determination of pharmaceutical equivalence of some enalapril maleate tablet generics marketed in Nigeria. 2018;5(2):129–135.

Deshmukh CD, Jain A. Diabetes mellitus: A review. 2015;3(3):224–230.

Khanam Q, Begum S, Khanom A, Choudhury T, Afroz R. Diabetes mellitus and gestational diabetes mellitus. J. Paediatr. Surg. Bangladesh. 2015;5(1):30–35.

Basit A, Riaz M, Fawwad A. Glimepiride: Evidence-based facts, trends and observations. Vasc. Health Risk Manag. 2012;8(1):463–472.

Jure H, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. Jama. 2008;299(13):1561.

Muller G. The mode of action of the antidiabetic drug glimepiride-beyond insulin secretion. Curr. Med. Chem. Endocr. Metab. Agents. 2005;5(6):499–518.

Chauhan N. Laboratory diagnosis of HbA1c: A review. J. Nanomedicine Res. 2017;5(4):1–10.

Schütze D. One-dimensional diffusions with discontinuous scale. Zeitschrift für Wahrscheinlichkeitstheorie und Verwandte Gebiete. 1979;49(1):97–104.

Bansal N. Prediabetes diagnosis and treatment: A review. World J. Diabetes. 2015;6(2):296.

Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-induced diabetic nude mouse model: Differences between animals from different sources. Comp. Med. 2011;61(4):356–360.

Gajdošík A, Gajdošíková A, Štefek M, Navarová J, Hozová R. Streptozotocin-induced experimental diabetes in male wistar rats. Gen. Physiol. Biophys. 1999;18(Spec. Iss.):54–62.

Khawaja Z, Wilcox SC. NIH Public Access. 2012;9(8):975–982.

Bergstrand R, et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br. J. Clin. Pharmacol. 1985;19(5):605–611.

Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark. Insights. 2016;11:95–104.

Ran J, et al. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: An implication for hypertension-related insulin resistance. Metabolism. 2006;55(4):478–488.

Allen Peter James, Bennett Kellie. SPSS for the health and behavioural sciences (1st Ed). Thomson Learning, South Melbourne, Vic; 2007.

Weir GC, Clore ET, Zmachinski CJ, Bonnerweir S. Islet secretion in a new experimental model for non-insulin dependent diabetes. Diabetes. 1981;30: 590–5.

Gokhale MS, Shah DH, Hakim Z, Santani DD, Goyal RK. Effect of chronic treatment with amlodipine in non-insulin-dependent diabetic rats. Pharm Res. 1998;37:455– 9.

Draznin B, Sussman KE, Eckel RH, Kao M, Yost F, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest. 1988;82: 1848–52.

Limula O, Shimamoto K, Matsuda K, Masuda A, Takizawa H, Higashiura HK, Miyazki Y, Hirata A, Ura N, Nakagawa M. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose— fed hypertensive rats and essential hypertensives. Am J Hypertens. 1995;8: 353–7.

Moan A, Hoieggen A, Nordby G, Eide IK, Kjeidsen SE. Effects of losartan on insulin sensitivity in severe hypertension: Connections through sympathetic nervous system activity? J Hum Hypertens. 1995;9:S45–50.

Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19: 403–18.

Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care. 1991;14:39– 47.